You are here

FDA Accepts Supplemental NDA For Intravenous Remodulin

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today that its intravenous Remodulin supplemental New Drug Application (sNDA) has been accepted for review by the United States Food and Drug Administration (FDA). The sNDA was submitted on January 30, 2004 to add the intravenous route of delivery to the Remodulin label for the treatment of patients with pulmonary arterial hypertension. The FDA has until November 30, 2004 to issue an action letter for the sNDA.

"We are pleased to see that our accelerated efforts to bring broader treatment options to the pulmonary hypertension community have satisfied the threshold standards at the FDA," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer.

Source: United Therapeutics Corporation

Recent Headlines

Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring